Multi-Peptide Protocol

Anti-Aging & Longevity: Epithalon + GHK-Cu + MOTS-c

These compounds are research chemicals. Epithalon, GHK-Cu, and MOTS-c are not FDA-approved for human use. This protocol is for educational purposes only.
Contraindications — Do Not Use If:

Active cancer or history of cancer. Epithalon activates telomerase, which is upregulated in the majority of human cancers. Telomerase activation in individuals with occult or active malignancies may promote tumor cell immortalization and proliferation.[1]

Autoimmune conditions. GHK-Cu and MOTS-c have immune-modulating properties. GHK-Cu modulates inflammatory cytokines, and MOTS-c influences immune cell metabolism via AMPK. In individuals with autoimmune diseases (e.g., lupus, rheumatoid arthritis, multiple sclerosis), these peptides may unpredictably alter immune function.[2]

Pregnancy or breastfeeding. No reproductive toxicology data exist for any of these three compounds in humans. Their effects on fetal development and lactation are unknown.

Children and adolescents. No pediatric safety data are available. Telomerase modulation, tissue remodeling, and metabolic reprogramming carry unpredictable risks during development.

Active organ transplant recipients on immunosuppression. Immune-modulating effects of GHK-Cu and MOTS-c may interfere with transplant immunosuppression regimens.

Known copper hypersensitivity or Wilson's disease. GHK-Cu delivers copper; individuals with copper metabolism disorders should not use this peptide.[3]

Combination Not Studied in Humans

Epithalon, GHK-Cu, and MOTS-c have each been studied individually in preclinical and limited clinical settings. However, this three-peptide combination has NOT been evaluated in any published human trial. The rationale for combining them is entirely theoretical, based on their complementary anti-aging mechanisms. There is no published safety data for concurrent use of all three compounds.

Rationale for Combination

This protocol targets three distinct hallmarks of aging through complementary mechanisms: telomere maintenance (Epithalon), extracellular matrix remodeling and tissue repair (GHK-Cu), and mitochondrial function with metabolic regulation (MOTS-c). The rationale is that addressing multiple aging pathways simultaneously may produce broader anti-aging effects than any single compound alone.

Epithalon: Telomerase Activation & Circadian Regulation

Epithalon (Epitalon, AEDG peptide) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the active fraction of the pineal gland extract Epithalamin, developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology:

  • Telomerase activation: Epithalon has been shown to activate telomerase in human somatic cells, inducing elongation of telomeres in fibroblast and CD8+ T-cell cultures. Telomere shortening is a primary hallmark of cellular aging, and telomerase reactivation may extend replicative lifespan.[1][4]
  • Circadian rhythm regulation: As a pineal-derived peptide, Epithalon modulates melatonin synthesis and may help restore age-related decline in circadian rhythm amplitude. Proper circadian function is critical for DNA repair, immune surveillance, and metabolic homeostasis.[5]
  • Antioxidant enzyme upregulation: In animal models, Epithalon increased the activity of superoxide dismutase (SOD) and other antioxidant enzymes, potentially reducing oxidative DNA damage.[6]
  • Longevity data: In rodent studies, Epithalamin (the parent extract) extended mean and maximum lifespan. These are among the most cited longevity results for any peptide intervention, though they have not been replicated in human trials.[5]

GHK-Cu: Tissue Remodeling & Anti-Inflammatory

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. Its concentration declines significantly with age (from ~200 ng/mL at age 20 to ~80 ng/mL by age 60):

  • Collagen synthesis and remodeling: GHK-Cu stimulates collagen types I, III, and V synthesis in fibroblasts. It also promotes decorin production and attracts immune cells to wound sites, accelerating tissue remodeling.[3][7]
  • Anti-inflammatory gene regulation: Broad Connectivity Map analysis revealed that GHK-Cu modulates expression of over 4,000 human genes, with significant upregulation of genes involved in tissue repair and downregulation of inflammatory and tissue-destructive pathways.[8]
  • Wound healing: GHK-Cu accelerates wound contraction, angiogenesis, and re-epithelialization in multiple animal models. It is one of the best-characterized wound-healing peptides.[3]
  • Skin and hair: Topical GHK-Cu has been shown to improve skin density, elasticity, and firmness in controlled trials, and to stimulate hair follicle growth.[7]

MOTS-c: Mitochondrial-Derived Metabolic Regulator

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded in the mitochondrial genome. It was discovered in 2015 and represents a new class of mitochondrial-derived peptides (MDPs):

  • AMPK activation: MOTS-c activates AMP-activated protein kinase (AMPK), the master metabolic sensor. AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis while inhibiting mTOR-driven anabolic processes associated with aging.[9]
  • Exercise mimetic: In mouse models, MOTS-c administration improved physical performance, increased metabolic rate, and prevented age-related and diet-induced obesity — effects resembling those of regular exercise.[10]
  • Glucose metabolism: MOTS-c enhances insulin sensitivity and glucose uptake independent of insulin signaling, primarily through AMPK-mediated GLUT4 translocation. This makes it of particular interest for age-related metabolic decline.[9]
  • Stress response and nuclear translocation: Under metabolic stress, MOTS-c translocates to the nucleus where it regulates adaptive gene expression via interaction with the antioxidant response element (ARE) pathway.[11]

Per-Component Dosing

The following dosing information reflects commonly reported protocols from research literature and clinical compounding practice. Individual responses vary significantly, and dosing should always be guided by a supervising clinician.

Parameter Epithalon GHK-Cu MOTS-c
Typical dose 5 – 10 mg 1 – 3 mg (SubQ)
or topical		 5 – 10 mg
Frequency Daily (during cycle) Daily (SubQ) or
2× daily (topical)		 3 – 5× per week
Route Subcutaneous Subcutaneous or topical Subcutaneous
Cycle length 10 – 20 days Continuous use OK 4 – 8 weeks
Cycles per year 2 – 3 cycles N/A (continuous) 2 – 3 cycles
Reconstitution Bacteriostatic water Bacteriostatic water (SubQ) Bacteriostatic water
Storage Refrigerated (2–8 °C) Refrigerated (2–8 °C) Refrigerated (2–8 °C)
Administration Note

Epithalon is typically administered as a short intensive course (10–20 consecutive days) rather than continuous long-term use. GHK-Cu can be used subcutaneously for systemic effects or applied topically (cream or serum) for localized skin benefits. MOTS-c is best administered in the morning before exercise or fasting, as its AMPK-activating effects synergize with metabolic stress.

Cycle Structure

Epithalon Cycles

  • Active cycle: 5–10 mg subcutaneously daily for 10–20 consecutive days
  • Off-cycle: 4–6 months between cycles
  • Frequency: 2–3 cycles per year is the most commonly reported schedule
  • Epithalon's effects on telomerase are believed to persist well beyond the active dosing window, which is why extended off-periods are standard[4]

GHK-Cu (Continuous)

  • SubQ protocol: 1–3 mg subcutaneously daily, continuous use
  • Topical protocol: Apply GHK-Cu cream or serum to face/target areas twice daily, continuous use
  • GHK-Cu is a naturally occurring peptide with a well-established safety profile at physiological doses. There is no established need for cycling, though periodic breaks (1–2 weeks every 3–4 months) are sometimes recommended anecdotally
  • Topical use is most appropriate for skin-specific goals (wrinkle reduction, elasticity, hair growth); SubQ is preferred for systemic tissue-remodeling effects[3]

MOTS-c Cycles

  • Active cycle: 5–10 mg subcutaneously 3–5× per week for 4–8 weeks
  • Off-cycle: 4 weeks off between cycles
  • MOTS-c is typically dosed on training days or in the morning fasted for synergy with natural AMPK activation
  • Start at the lower dose (5 mg, 3×/week) and titrate based on tolerance and metabolic response

Combined Schedule Example

  • Months 1–2: MOTS-c cycle (4–8 weeks) + GHK-Cu daily (continuous)
  • Month 3: Epithalon cycle (10–20 days) + GHK-Cu daily (continuous). MOTS-c off.
  • Months 4–5: GHK-Cu daily only. Both Epithalon and MOTS-c off.
  • Month 6: Restart MOTS-c cycle + GHK-Cu daily. Repeat schedule.

Monitoring Guidance

Because these compounds target fundamental cellular processes (telomere maintenance, tissue remodeling, mitochondrial metabolism), monitoring should be comprehensive and multisystem.

What to Track

  • Telomere length testing (optional): Telomere length measurement (e.g., via qPCR-based assays like those from LifeLength or RepeatDx) can be performed at baseline and annually. This is expensive and has significant inter-assay variability, making it an imperfect biomarker. Trends over years are more informative than single measurements.[4]
  • Skin quality and wound healing assessment: For GHK-Cu, document skin elasticity, hydration, wrinkle depth, and wound healing speed. Standardized photography at consistent intervals is helpful.
  • Body composition: DEXA or bioimpedance at baseline and every 2–3 months to track lean mass, fat mass, and bone mineral density changes.
  • Fasting glucose and insulin: MOTS-c affects glucose metabolism via AMPK activation. Monitor at baseline and monthly during MOTS-c cycles.[9]
  • Inflammatory markers: CRP (C-reactive protein) and IL-6 at baseline and quarterly. GHK-Cu and MOTS-c both modulate inflammatory pathways.[2]
  • Comprehensive metabolic panel: Liver function, kidney function, and electrolytes at baseline and at least every 3 months.
  • Complete blood count: Monitor for any hematological changes, particularly given Epithalon's effects on cellular proliferation.
  • Sleep quality and circadian assessment: Epithalon modulates melatonin. Track sleep latency, duration, and quality using validated instruments or wearable devices.

When to Stop

  • Any sign of allergic reaction (urticaria, angioedema, anaphylaxis)
  • Unexplained changes in blood counts (potential sign of abnormal cellular proliferation)
  • New skin lesions, moles, or masses (given telomerase-activating properties of Epithalon)
  • Signs of copper toxicity with GHK-Cu: nausea, abdominal pain, liver enzyme elevation
  • Persistent GI effects or significant blood glucose changes with MOTS-c
  • Any worsening of autoimmune symptoms
  • Abnormal liver or kidney function on routine labs

Side Effects

Epithalon

  • Generally well-tolerated: In the available Russian clinical literature and anecdotal reports, Epithalon is reported to have an excellent safety profile at standard doses.[5]
  • Injection site reactions: Mild redness, swelling, or pain at the injection site. Self-limiting.
  • Drowsiness or sleep changes: Due to melatonin modulation, some users report increased sleepiness. This is generally considered beneficial but may require timing adjustment.
  • Theoretical concern: Telomerase activation could theoretically promote growth of pre-existing occult tumors. This is the primary safety concern with any telomerase activator.[1]

GHK-Cu

  • Rare allergic reactions: Hypersensitivity to the peptide or to copper. Skin patch testing may be appropriate for topical use in sensitive individuals.
  • Copper sensitivity: Individuals with copper metabolism disorders (Wilson's disease, copper storage diseases) must avoid GHK-Cu. Even in healthy individuals, excessive copper intake should be avoided.[3]
  • Injection site reactions (SubQ): Mild local redness or irritation, typically self-limiting.
  • Skin irritation (topical): Mild redness or sensitivity with topical formulations, particularly in individuals with reactive skin.

MOTS-c

  • Transient GI effects: Mild nausea, abdominal discomfort, or changes in bowel habits during the first 1–2 weeks of use. Usually self-limiting.[9]
  • Injection site reactions: Redness, swelling, or mild pain at the injection site.
  • Hypoglycemia risk: MOTS-c enhances glucose uptake. When combined with fasting or diabetes medications, there is a theoretical risk of low blood sugar. Monitor glucose if used in combination with anti-diabetic agents.
  • Fatigue (paradoxical): Some users report transient fatigue in the first few days, possibly related to metabolic reprogramming. Typically resolves within a week.

Drug Interactions

No formal drug interaction studies have been conducted for this three-peptide combination. The following are theoretical considerations based on known mechanisms:

  • Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, corticosteroids): GHK-Cu and MOTS-c both have immune-modulating properties. Concurrent use with immunosuppressants may produce unpredictable immune effects, potentially compromising immunosuppression or causing immune dysregulation.[2]
  • Diabetes medications (insulin, metformin, sulfonylureas, SGLT2 inhibitors): MOTS-c activates AMPK (similar to metformin's mechanism) and enhances glucose uptake. Concurrent use may potentiate hypoglycemia or require dose adjustment of anti-diabetic medications.[9]
  • Anticoagulants (warfarin, heparin, DOACs): GHK-Cu promotes wound healing and modulates inflammatory pathways that intersect with coagulation. Monitor coagulation parameters if using GHK-Cu with anticoagulants.
  • Copper supplements: Additional copper intake on top of GHK-Cu may risk copper overload. Avoid concurrent copper supplementation without serum copper and ceruloplasmin monitoring.[3]
  • Melatonin supplements: Epithalon modulates endogenous melatonin synthesis. Concurrent exogenous melatonin may result in supraphysiological melatonin levels. Adjust or discontinue melatonin supplements during Epithalon cycles.[5]
  • Cancer therapies (chemotherapy, radiation, immunotherapy): Telomerase activation (Epithalon), tissue proliferation (GHK-Cu), and metabolic reprogramming (MOTS-c) may all interfere with cancer treatment mechanisms. Absolutely contraindicated during active cancer treatment.

Video Resources

The science of skin aging, collagen, and cellular rejuvenation — Huberman Lab

Anti-aging peptides including GHK-Cu and longevity compounds — Huberman Lab

References

  1. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592. doi:10.1023/A:1025493705728. PMID: 12937682.
  2. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative Medicine and Cellular Longevity. 2012;2012:324832. doi:10.1155/2012/324832. PMID: 22666519.
  3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730.
  4. Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine. 2004;137(5):503-506. doi:10.1023/B:BEBM.0000038164.49947.8c. PMID: 15455129.
  5. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. doi:10.1007/s10522-009-9249-8. PMID: 19830585.
  6. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters. 2003;24(3-4):233-240. PMID: 14523363.
  7. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. doi:10.1163/156856208784909435. PMID: 18644225.
  8. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. BioMed Research International. 2014;2014:151479. doi:10.1155/2014/151479. PMID: 25003106.
  9. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009. PMID: 25738459.
  10. Kim SJ, Mehta HH, Wan J, et al. Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging (Albany NY). 2018;10(6):1239-1256. doi:10.18632/aging.101463. PMID: 29886458.
  11. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(3):516-524.e7. doi:10.1016/j.cmet.2018.06.008. PMID: 29983382.
  12. Reynolds JA, Bhatt DL, Engelen RG, et al. The role of mitochondrial-derived peptides in cardiovascular disease. Frontiers in Cardiovascular Medicine. 2021;8:700975. doi:10.3389/fcvm.2021.700975. PMID: 34447790.